Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02978586 · ClinicalTrials.gov registry record

A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors

A clinical trial of Breast Cancer and Prostate Cancer, sponsored by Case Comprehensive Cancer Center.

Completed
Registry status
8
Enrollment target
1
Study location

NCT02978586 is a study of Breast Cancer and Prostate Cancer that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 8 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02978586, a study of Breast Cancer and Prostate Cancer, has completed, sponsored by Case Comprehensive Cancer Center.

COMPLETED
Registry status
8 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to see if positron emission tomography/ magnetic resonance imaging (PET/MRI) can be used to monitor the effectiveness of cancer treatment using an investigational radioactive drug called \[Ga-68\]PSMA.

Interventions

  • DEVICE [Ga-68]PSMA PET/MR

Study Locations (1)

Ohio

  • University Hospitals, Case Comprehensive Cancer Center - Cleveland

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2018-03-14
Est. Completion 2019-10-25

Sponsor

Case Comprehensive Cancer Center

407 total trials

What the Registry Record Tells You About NCT02978586

The ClinicalTrials.gov registry entry for NCT02978586 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which [Ga-68]PSMA PET/MR is the first listed.

NCT02978586 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT02978586 about?

NCT02978586 is a clinical study titled "A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors". The purpose of this study is to see if positron emission tomography/ magnetic resonance imaging (PET/MRI) can be used to monitor the effectiveness of cancer treatment using an investigational radioactive drug called \[Ga-68\]PSMA.

What is the current status of trial NCT02978586?

This trial is currently completed. The enrollment target is 8 participants. The study started on 2018-03-14. Estimated completion is 2019-10-25.

What conditions does trial NCT02978586 study?

This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Prostate-specific Membrane Antigen Positive Tumors.

What interventions are being tested in trial NCT02978586?

The interventions under investigation include: [Ga-68]PSMA PET/MR (DEVICE).

Who is sponsoring clinical trial NCT02978586?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02978586 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.